32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

Bibliographic Details
Main Authors: Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, Alessio Cortellini, James Clark, Emma Mi, Sanna Livanainen, Daria Gramenitskaya, Kevin O’Brien, Jussi Koivunen, Sweta Jonnalagadda, Shanker Polsani, Rahim Jiwani, Nitika Sharma, Chipman Stroud, Paul Walker, David Pinato
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-40e3e79742894243b4bf4802423f20b5
record_format Article
spelling doaj-40e3e79742894243b4bf4802423f20b52020-12-11T10:01:12ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.003232 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational studyAbdul Rafeh Naqash0Mahvish Muzaffar1Shravanti Macherla2Alessio Cortellini3James Clark4Emma Mi5Sanna Livanainen6Daria Gramenitskaya7Kevin O’Brien8Jussi Koivunen9Sweta Jonnalagadda10Shanker Polsani11Rahim Jiwani12Nitika Sharma13Chipman Stroud14Paul Walker15David Pinato16Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA Aff1 0000 0001 2191 0423grid.255364.3Division of Hematology/OncologyEast Carolina University 600 Moye Boulevard 27834 Greenville NC USA Aff1 Medical OncologySt. Salvatore Hospital L’Aquila Italy Melanoma and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK3Imperial College London, London, UK4University of Oulu, MRC Oulu, Oulu, Finland3Imperial College London, London, UK5East Carolina University, Greenville, NC, USA4University of Oulu, MRC Oulu, Oulu, Finland5East Carolina University, Greenville, NC, USA5East Carolina University, Greenville, NC, USA5East Carolina University, Greenville, NC, USA5East Carolina University, Greenville, NC, USA6Genentech, San-Francisco, CA, USA7Circulogene, Birmingham, AL, USA3Imperial College London, London, UK
collection DOAJ
language English
format Article
sources DOAJ
author Abdul Rafeh Naqash
Mahvish Muzaffar
Shravanti Macherla
Alessio Cortellini
James Clark
Emma Mi
Sanna Livanainen
Daria Gramenitskaya
Kevin O’Brien
Jussi Koivunen
Sweta Jonnalagadda
Shanker Polsani
Rahim Jiwani
Nitika Sharma
Chipman Stroud
Paul Walker
David Pinato
spellingShingle Abdul Rafeh Naqash
Mahvish Muzaffar
Shravanti Macherla
Alessio Cortellini
James Clark
Emma Mi
Sanna Livanainen
Daria Gramenitskaya
Kevin O’Brien
Jussi Koivunen
Sweta Jonnalagadda
Shanker Polsani
Rahim Jiwani
Nitika Sharma
Chipman Stroud
Paul Walker
David Pinato
32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
Journal for ImmunoTherapy of Cancer
author_facet Abdul Rafeh Naqash
Mahvish Muzaffar
Shravanti Macherla
Alessio Cortellini
James Clark
Emma Mi
Sanna Livanainen
Daria Gramenitskaya
Kevin O’Brien
Jussi Koivunen
Sweta Jonnalagadda
Shanker Polsani
Rahim Jiwani
Nitika Sharma
Chipman Stroud
Paul Walker
David Pinato
author_sort Abdul Rafeh Naqash
title 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
title_short 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
title_full 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
title_fullStr 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
title_full_unstemmed 32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study
title_sort 32 c-reactive protein (crp) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. results from a multi-center international observational study
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT abdulrafehnaqash 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT mahvishmuzaffar 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT shravantimacherla 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT alessiocortellini 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT jamesclark 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT emmami 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT sannalivanainen 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT dariagramenitskaya 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT kevinobrien 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT jussikoivunen 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT swetajonnalagadda 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT shankerpolsani 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT rahimjiwani 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT nitikasharma 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT chipmanstroud 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT paulwalker 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
AT davidpinato 32creactiveproteincrpasaprognosticbiomarkerinadvancednonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsresultsfromamulticenterinternationalobservationalstudy
_version_ 1724386651411578880

Similar Items